123 related articles for article (PubMed ID: 30773349)
1. Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.
Saleh K; Saada E; Auger N; Mayache-Badis L; Casiraghi O; Bidault F; Bahleda R; Even C
Oral Oncol; 2019 Apr; 91():129-131. PubMed ID: 30773349
[No Abstract] [Full Text] [Related]
2. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
5. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
6. Duration of trastuzumab maintenance in HER2-positive metastatic breast cancer patients with radiological complete remission: Robust predictive markers are needed!
Altundag K
J BUON; 2020; 25(2):1269. PubMed ID: 32521942
[No Abstract] [Full Text] [Related]
7. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
Jelinek MJ; Vokes EE
J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
[No Abstract] [Full Text] [Related]
8. Trastuzumab-emtansine might affect the survival outcome by reversing increased platelet-to-lymphocyte ratio in HER2-positive metastatic breast cancer patients.
Altundag K
J BUON; 2019; 24(1):407. PubMed ID: 30942001
[No Abstract] [Full Text] [Related]
9. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
10. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
Kunzke T; Hölzl FT; Prade VM; Buck A; Huber K; Feuchtinger A; Ebert K; Zwingenberger G; Geffers R; Hauck SM; Haffner I; Luber B; Lordick F; Walch A
Clin Transl Med; 2021 Sep; 11(9):e547. PubMed ID: 34586736
[No Abstract] [Full Text] [Related]
13. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K; Aoe K; Kozuki T; Ohashi K; Ninomiya K; Ichihara E; Kubo T; Ninomiya T; Chikamori K; Harada D; Nogami N; Hirata T; Hinotsu S; Toyooka S; Kiura K
J Thorac Oncol; 2018 Feb; 13(2):273-279. PubMed ID: 29313813
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-based therapy is effective for salivary duct carcinoma: Case report and review of the literature.
Wu S; Quan R; Han L
Oral Oncol; 2019 Apr; 91():121-122. PubMed ID: 30827840
[No Abstract] [Full Text] [Related]
15. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection.
Scully EP; Rutishauser RL; Simoneau CR; Delagrèverie H; Euler Z; Thanh C; Li JZ; Hartig H; Bakkour S; Busch M; Alter G; Marty FM; Wang CC; Deeks SG; Lorch J; Henrich TJ
Ann Oncol; 2018 Oct; 29(10):2141-2142. PubMed ID: 30032204
[No Abstract] [Full Text] [Related]
16. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis.
Lee KWC; Lord SJ; Kasherman L; Marschner I; Stockler M; Gralla R; Yang JC; Mok T; Lee CK
Acta Oncol; 2020 Jan; 59(1):96-100. PubMed ID: 31552770
[No Abstract] [Full Text] [Related]
17. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
19. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
20. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]